NASDAQ
30.06.25 | 21:59
7,220 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.06. | Cogent Biosciences, Inc.: Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing | 1 | GlobeNewswire (USA) | ||
| 05.06. | Cogent Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.05. | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Cogent Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| COGENT BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 06.05. | Cogent Biosciences reports Q1 results | 2 | Seeking Alpha | ||
| 25.04. | Cogent Biosciences, Inc.: Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders | 3 | GlobeNewswire (USA) | ||
| 25.03. | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 25.02. | Cogent Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.02. | Cogent Biosciences, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 25.02. | Cogent Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.02. | Cogent Biosciences, Inc.: Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 16.01. | Hedge Fund and Insider Trading News: Bill Ackman, Scott Bessent, Alden Global Capital, Saba Capital, Point72 Asset Management, Citadel Investment Group, Cogent Biosciences Inc (COGT), Immunovant Inc (IMVT), and More | 4 | Insider Monkey | ||
| 13.01. | Cogent Biosciences sets key 2025 milestones for drug trials | 1 | Investing.com | ||
| 13.01. | Cogent Biosciences legt wichtige Meilensteine für Medikamentenstudien bis 2025 fest | 2 | Investing.com Deutsch | ||
| 09.12.24 | Cogent Biosciences, Inc.: Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients | 400 | GlobeNewswire (Europe) | 56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS 89% of patients had >50% decrease in serum tryptase by... ► Artikel lesen | |
| 08.12.24 | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | 285 | GlobeNewswire (Europe) | 52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with... ► Artikel lesen | |
| 06.08.24 | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results | 486 | GlobeNewswire (Europe) | SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 2Q 2024 with $390 million, sufficient to fund... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 47,005 | 0,00 % | Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business | SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business sector Acquisition marks the formation of a rare tumor... ► Artikel lesen | |
| VERA THERAPEUTICS | 23,560 | 0,00 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| ARTELO BIOSCIENCES | 13,180 | 0,00 % | Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain | First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 42,050 | 0,00 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 18,190 | 0,00 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| NURIX THERAPEUTICS | 11,390 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,050 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| TANGO THERAPEUTICS | 5,120 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ... | BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen | |
| EVOTEC | 7,082 | -1,69 % | Übernahmefantasie angeheizt: Evotec: Neue Hoffnung in der Nierenforschung befeuert Kurs | © Foto: Christian Charisius - dpaDas Hamburger Biotech-Schmiede beteiligt sich an einer großangelegten Studie zu Nierenversagen. Das könnte Evotec völlig neue Marktchancen bescheren.Evotec hat eine... ► Artikel lesen | |
| QIAGEN | 40,610 | -0,67 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 43,490 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
| CELCUITY | 13,350 | 0,00 % | Celcuity Inc.: Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib | • In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer ("mCRPC"),the six-month radiographic progression... ► Artikel lesen | |
| VOR BIOPHARMA | 1,610 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,250 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen | |
| QUANTUM-SI | 1,960 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen |
Das Unternehmen COGENT BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 7,220 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGENT BIOSCIENCES INC finden Sie auf Wallstreet Online.